Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC)’s stock price has gone decline by -9.93 in comparison to its previous close of 1.51, however, the company has experienced a -22.29% decrease in its stock price over the last five trading days. GlobeNewsWire reported 2024-04-01 that – New clinical, PK and PD data from novel CDK2/9 inhibitor fadraciclib monotherapy studies support ongoing development program in patients with solid tumors and lymphoma –
Is It Worth Investing in Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC) Right Now?
CYCC has 36-month beta value of 0.62. Analysts have mixed views on the stock, with 1 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for CYCC is 1.20M, and currently, short sellers hold a 3.20% ratio of that float. The average trading volume of CYCC on April 30, 2024 was 110.90K shares.
CYCC’s Market Performance
CYCC stock saw a decrease of -22.29% in the past week, with a monthly decline of -35.54% and a quarterly a decrease of -40.35%. The volatility ratio for the week is 19.29%, and the volatility levels for the last 30 days are 11.96% for Cyclacel Pharmaceuticals Inc (CYCC). The simple moving average for the past 20 days is -29.17% for CYCC’s stock, with a -71.76% simple moving average for the past 200 days.
Analysts’ Opinion of CYCC
Many brokerage firms have already submitted their reports for CYCC stocks, with Oppenheimer repeating the rating for CYCC by listing it as a “Outperform.” The predicted price for CYCC in the upcoming period, according to Oppenheimer is $17 based on the research report published on July 18, 2022 of the previous year 2022.
ROTH Capital, on the other hand, stated in their research note that they expect to see CYCC reach a price target of $24. The rating they have provided for CYCC stocks is “Buy” according to the report published on April 27th, 2020.
CYCC Trading at -40.11% from the 50-Day Moving Average
After a stumble in the market that brought CYCC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -89.70% of loss for the given period.
Volatility was left at 11.96%, however, over the last 30 days, the volatility rate increased by 19.29%, as shares sank -33.66% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -48.97% lower at present.
During the last 5 trading sessions, CYCC fell by -22.29%, which changed the moving average for the period of 200-days by -84.89% in comparison to the 20-day moving average, which settled at $1.8856. In addition, Cyclacel Pharmaceuticals Inc saw -49.06% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CYCC starting from Rombotis Spiro George, who purchase 6,070 shares at the price of $3.31 back on Dec 21 ’23. After this action, Rombotis Spiro George now owns 68,658 shares of Cyclacel Pharmaceuticals Inc, valued at $20,122 using the latest closing price.
McBarron Paul, the of Cyclacel Pharmaceuticals Inc, purchase 1,886 shares at $3.31 during a trade that took place back on Dec 21 ’23, which means that McBarron Paul is holding 33,378 shares at $6,252 based on the most recent closing price.
Stock Fundamentals for CYCC
Current profitability levels for the company are sitting at:
- -61.55 for the present operating margin
- 0.06 for the gross margin
The net margin for Cyclacel Pharmaceuticals Inc stands at -53.86. The total capital return value is set at -40.14. Equity return is now at value -218.87, with -124.25 for asset returns.
Based on Cyclacel Pharmaceuticals Inc (CYCC), the company’s capital structure generated 0.06 points at debt to capital in total, while cash flow to debt ratio is standing at -435.46. The debt to equity ratio resting at 0.06. The interest coverage ratio of the stock is 239.38.
Currently, EBITDA for the company is -30.27 million with net debt to EBITDA at 0.13. When we switch over and look at the enterprise to sales, we see a ratio of -3.69. The receivables turnover for the company is 0.14for trailing twelve months and the total asset turnover is 0.05. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.91.
Conclusion
To put it simply, Cyclacel Pharmaceuticals Inc (CYCC) has had a bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
